[1] Caturegli P, De Remigis A, Chuang K, et al. Hashimoto's thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid,2013,23(2):142-150.
[2] Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev,2020,19(10):102649.
[3] Mikulska AA, Kara niewicz-Łada M, Filipowicz D, et al. Metabolic characteristics of Hashimoto's thyroiditis patients and the role of microelements and diet in the disease management-An overview. Int J Mol Sci, 2022,23(12):6580.
[4] Ragusa F, Fallahi P, Elia G, et al. Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab, 2019,33(6):101367.
[5] Lepez T, Vandewoestyne M, Deforce D. Fetal microchimeric cells in autoimmune thyroid diseases: harmful, beneficial or innocent for the thyroid gland? Chimerism, 2013,4(4):111-118.
[6] Mynster Kronborg T, Frohnert Hansen J, Nielsen CH, et al. Effects of thecommercial flame retardant mixture DE-71 on cytokine production by human immune cells. PLoS One, 2016,11(4):e0154621.
[7] Wiersinga WM. Clinicalrelevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul), 2016,31(2):213-222.
[8] Gong B, Wang C, Meng F, et al. Associationbetween gut microbiota and autoimmune thyroid disease: A systematic review and Meta-analysis. Front Endocrinol (Lausanne), 2021,12:774362.
[9] Aghini Lombardi F, Fiore E, Tonacchera M, et al. The effect of voluntary iodine prophylaxis in a small rural community: the Pescopagano survey 15 years later. J Clin Endocrinol Metab, 2013,98(3):1031-1039.
[10] Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science, 1997,275(5302):960-963.
[11] Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Pol Arch Intern Med,2022,132(3):16222.
[12] Anyetei-Anum CS, Roggero VR, Allison LA. Thyroid hormone receptor localization in target tissues. J Endocrinol, 2018, 237(1):R19-R34.
[13] Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med,1987,316(13):764-770.
[14] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018,18(3):245-250.
[15] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,64(1):73-84.
[16] Wree A, Broderick L, Canbay A, et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol,2013,10(11):627-636.
[17] Luo W, Xu Q, Wang Q, et al. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep,2017,7:44612.
[18] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, 2010,52(5):1836-1846.
[19] Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology, 2006,131(3):934-945.
[20] Rada P, González-Rodríguez Á, García-Monzón C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis, 2020,11(9):802.
[21] Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab, 2015,21(5):739-746.
[22] Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab, 2016,23(4):591-601.
[23] Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne), 2023,13:1087260.
[24] Tacke F, Puengel T, Loomba R, et al. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol, 2023,79(2):552-566.
[25] Liao CJ, Huang PS, Chien HT, et al. Effects of thyroid hormones on lipid metabolism pathologies in non-alcoholic fatty liver disease. Biomedicines, 2022,10(6):1232.
[26] Muls E, Rosseneu M, Blaton V, et al. Serum lipids and apolipoproteins A-I, A-II and B in primary hypothyroidism before and during treatment. Eur J Clin Invest, 1984,14(1):12-15.
[27] Friis T, Pedersen LR. Serum lipids in hyper- and hypothyroidism before and after treatment. Clin Chim Acta,1987,162(2):155-163.
[28] Packard CJ, Shepherd J, Lindsay GM, et al. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab, 1993,76(5):1209-1216.
[29] Wiseman SA, Powell JT, Humphries SE, et al. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene. J Clin Endocrinol Metab,1993,77(1):108-112.
[30] Pazos F, Alvarez JJ, Rubiés-Prat J, et al. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab,1995,80(2):562-566.
[31] Araki O, Ying H, Zhu XG, et al. Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol, 2009,23(3):308-315.
[32] 陈怡,朱友,周希乔.甲状腺激素与非酒精性脂肪性肝病研究进展.实用肝脏病杂志,2023,26(1):145-148.
[33] Yetkin DO, Dogantekin B. The lipid parameters and lipoprotein(a) excess in Hashimoto thyroiditis. Int J Endocrinol, 2015,2015:952729.
[34] Torres-Peña JD, Arenas-de Larriva AP, Alcala-Diaz JF, et al. Different dietary approaches, non-alcoholic fatty liver disease and cardiovascular disease: A literature review. Nutrients, 2023,15(6):1483.
[35] Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol, 2018 ,68(2):335-352.
[36] Al-Muzafar HM, Alshehri FS, Amin KA. The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fat-carbohydrate diet-induced rat model of insulin resistance. Braz J Med Biol Res, 2021,54(8):e10782.
[37] Labenz C, Kostev K, Armandi A, et al. Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. United European Gastroenterol J, 2021,9(7):829-836.
[38] Loosen SH, Demir M, Kostev K, et al. Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol,2021,33(Suppl 1):e1008-e1012.
[39] Gor R, Siddiqui NA, Wijeratne Fernando R, et al. Unraveling the role of hypothyroidism in non-alcoholic fatty liver disease pathogenesis: Correlations, conflicts, and the current Stand. Cureus,2021,13(5):e14858.
[40] Zhang HF, Zhang QX, Feng YH, et al. Association of thyroid disease and risk of fatty liver disease: an exposure-wide Mendelian randomization study. Eur Rev Med Pharmacol Sci, 2023,27(23):11402-11411.
[41] Xiao R, Ni C, Cai Y, et al. Prevalence and impact of non-alcoholic fatty liver disease in patients with papillary thyroid carcinoma. Endocrine, 2023,80(3):619-629.
[42] Chung GE, Kim D, Kim W, et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol, 2012,57(1):150-156.
[43] Elshinshawy S, Elhaddad H, Abdel Alem S, et al. The interrelation between hypothyroidism and non-alcoholic fatty liver disease, a cross-sectional study. J Clin Exp Hepatol, 2023,13(4):638-648.
[44] Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci,2012,57(2):528-534.
[45] Bano A, Chaker L, Plompen EP, et al. Thyroid function and the risk of nonalcoholic fatty liver disease: The Rotterdam study. J Clin Endocrinol Metab, 2016,101(8):3204-3211.
[46] Manka P, Bechmann L, Best J, et al. Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis. Dig Dis Sci, 2019,64(8):2351-2358.
[47] Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev, 2014,13(9):981-1000.
[48] Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol, 2014 ,28(4):637-653.
[49] Sakurai Y, Kubota N, Yamauchi T, et al. Role of insulin resistance in MAFLD. Int J Mol Sci, 2021,22(8):4156.
[50] Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol, 2014,6(5):274-283.
[51] Li Q, Wang L, Wu J, et al. Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003-2018): cross-sectional study. BMJ Open, 2022,12(3):e058517. |
